
Please try another search
MEI Pharma, Inc., a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. It develops ME-344, an intravenous small molecule inhibitor mitochondrial oxidative phosphorylation to treat human epidermal growth factor receptor 2 negative breast cancer, colorectal cancer, and solid tumors. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
Name | Age | Since | Title |
---|---|---|---|
Nicholas R. Glover | 55 | 2013 | Independent Non-Executive Director |
Taheer Datoo | 32 | 2023 | Director |
James P. Flynn | 43 | 2023 | Independent Director |
Thomas C. Reynolds | 65 | 2013 | Independent Non-Executive Director |
Frederick W. Driscoll | 73 | 2018 | Independent Chairperson |
Steven Duncan Wood | 42 | 2023 | Independent Non-Executive Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review